"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to IMNM. [ FAQ on what and how to ask] For non-IMNM questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Clay B. Siegall Ph.D.
Headquarter: 18702 North Creek Parkway, Suite 100, Bothell, WA, United States, 98011
Industry: Biotechnology, Employees: 131
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
My Watchlist
